Other Causes of Reduced Pseudocholinesterase Activity Disease states Drugs (e.g., organophosphates, neostigmine , pyridostigmine) Effects: Prolonged paralysis , including diaphragm involvement Risk of respiratory failure Dibucaine Test Used to diagnose enzyme deficiency: Normal: ~80% inhibition Heterozygotes: 5060% Homozygotes: 2030% Management: Maintain sedation and mechanical ventilation Monitor recovery using train-of-four stimulation Other Contraindications History of malignant hyperthermia Conditions predisposing to hyperkalemia , including: Burns or major trauma (2472 hours post-injury) Neuromuscular disorders Myopathies Acute narrow-angle glaucoma or penetrating eye injury Side Effects Malignant hyperthermia (rare but fatal risk) Hyperkalemia (can be life-threatening) Risk of: Cardiac arrest Rhabdomyolysis Cardiac arrhythmias (bradycardia or tachycardia) Muscle pain (due to fasciculations) Increased intragastric pressure aspiration risk Increased intraocular pressure (contraindicated in glaucoma) Pharmacokinetics Routes: IV or IM Rapid metabolism by plasma pseudocholinesterase Not metabolized by acetylcholinesterase Key Parameters: Onset: 3060 seconds Duration: 610 minutes Half-life: 35 minutes Notes: Phase II block recovery may last 30 minutes or longer Duration depends on: Rate of receptor dissociation Plasma enzyme activity Drug Interactions Increase Duration of Action: Cholinesterase inhibitors (e.g., neostigmine , pyridostigmine) Administration of neostigmine & pyridostigmine to patients to reverse non-depolarizing skeletal muscle blockade has been shown to cause profound reductions of plasma pseudocholinesterase activity for several hours duration (Mirakhur et al, 1982), an effect that can mechanistically account for the observed prolongation of succinylcholine effect by these cholinesterase inhibitors (Sunew & Hicks, 1978
Through multiple rounds of sketching, prototyping, and refinement, the team ensured the final design remained both authentic and elegantclear and intuitive in form, yet deeply rooted in tradition
As an honors course, topics are covered in greater depth with challenging problems and at an accelerated pace with enrichment
The FDA has authorized the marketing of three Vuse vaping devices, marking the first ever electronic nicotine delivery system (ENDS) products authorized by the FDA through the Premarket Tobacco Product Application (PMTA) pathway
